Penumbra’s THUNDERBOLT clearance strengthens Boston Scientific’s pending vascular device bet
Find out how Penumbra’s THUNDERBOLT FDA clearance could reshape stroke thrombectomy, CAVT adoption, and medtech competition.
Why Rapid Medical’s DISTALS data could reshape treatment expectations in smaller stroke vessels
Distal stroke has long lacked device options. Rapid Medical’s TIGERTRIEVER 13 data now tests whether small-vessel thrombectomy can scale.
What Boston Scientific’s $14.5bn Penumbra buyout means for stroke and clot intervention markets
Boston Scientific Corporation has announced a definitive agreement to acquire Penumbra, Inc. for approximately $14.5 billion, marking one of its largest acquisitions to date in the medical device sector. The deal, structured as approximately 73 percent cash and 27 percent stock, offers Penumbra shareholders $374 per share and is expected to close in 2026, subject […]